Advance in pathogenesis and therapy of pediatric dilated cardiomyopathy
10.3760/cma.j.issn.1673-4408.2011.02.023
- VernacularTitle:儿童扩张型心肌病发病机制及治疗进展
- Author:
Xu ZHANG
- Publication Type:Journal Article
- Keywords:
Dilated cardiomyopathy;
Children;
Pathogenesis;
Carvedilol
- From:
International Journal of Pediatrics
2011;38(2):169-172
- CountryChina
- Language:Chinese
-
Abstract:
Dilated cardiomyopathy (DCM) is the most commom form of cardiomyopathy in children,including genetic and non-genetic pathogenesis. Due to the unclear aetiology and pathogenesis, DCM seriously impairs the quality of patients' life and reduces patients' survival time. Heart failure is one of the main clinical manifestations of DCM. Carvedilol, the third generation of β-adrenergic receptor blocker, is a nonselective β-blocker and a selective α1-blocker as well. It can prevent the development of ventricular remodeling and improve myocardial contractility and has been widely used in treating chronic cardiac insufficiency in adults. This article summarized some new progresses in pathogenesis and therapy of pediatric dilated cardiomyopathy.
